a lot of good info in announcement, page-3

rebel,
PNO does not go it alone, something some of us anticipated since some time, hence no interest in CRs or something of the sort.

Licensing deals are excactly the process and business strategy of the larger sister company in Perth and a strong support for future revenue for the company.

As expected, Jeff has been busy.


Pharma will not be named until such negotiations are sealed but the mention of international markets makes it clear that we are heading towards international exposure of our analgesic compounds, particularly Tripeptofen.

We know that Tripeptofen had approval in India and US before, therefore the referred analgesic composition is a direct reference to this compound.


Good times ahead,
I doubt the market will grasp the complexity of this ann, but in time we will look at an entirely different shareprice when those negotiations bear fruit.